
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.66641
Physical Medicine & Rehabilitation
Orthopedics
Sports Medicine
Insertional Achilles Tendinopathy Treated With Botulinum Toxin: A Case Report
Muacevic Alexander
Adler John R
Kim Alexander 1
Knobloch Alexander 1
Covey Carlton 1
1 Sports Medicine, David Grant Medical Center, Fairfield, USA
Alexander Kim aksep1985@gmail.com
11 8 2024
8 2024
16 8 e666416 8 2024
Copyright © 2024, Kim et al.
2024
Kim et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/278502-insertional-achilles-tendinopathy-treated-with-botulinum-toxin-a-case-report
Chronic insertional Achilles tendinopathy (IAT) is a common cause of recalcitrant heel pain. Patients present with pain localized to the Achilles tendon insertion at the calcaneus and have tenderness to palpation in this area on physical exam. Conservative management often includes an exercise prescription focusing on eccentric loading with limited dorsiflexion. Extracorporeal shockwave therapy and injection therapies including hypertonic dextrose and platelet-rich plasma (PRP) have shown some therapeutic benefit but evidence for injections is limited. IAT can often be recalcitrant to non-operative treatments, and cases are often referred for surgical debridement and decompression. Botulinum toxin A (BTX-A) has been used to treat several different musculoskeletal injuries, but there have been no published studies assessing the efficacy of BTX-A injections specifically for Achilles tendinopathy. This is a case of recalcitrant IAT treated with ultrasound-guided BTX-A.

prolotherapy
rehab protocol
sports ultrasound
insertional achilles tendinopathy
botulinum (botox)
==== Body
pmcIntroduction

Achilles tendinopathy is a chronic, overuse injury to the Achilles tendon and can be divided anatomically into insertional or mid-substance tendinopathy depending on the location of the injury. Insertional Achilles tendinopathy (IAT) is an overuse tendon injury that occurs at the distal portion of the Achilles tendon due to its insertion into the calcaneus [1]. Patients who develop IAT will often have posterior heel pain, stiffness, and swelling, with focal tenderness to palpation at the distal Achilles tendon and calcaneal insertion on physical exam [2]. While conservative treatments have shown to be effective in treating mid-substance Achilles tendinopathy, IAT is often resistant to non-operative treatment options, including strength training, eccentric exercises, orthotics, and NSAIDs, making IAT difficult to manage [2,3]. While some injection therapies including corticosteroid injections and platelet-rich plasma (PRP) injections have shown efficacy in treating mid-substance tendinopathy, these treatments have not shown the same clinical outcomes in IAT [2]. Botulinum neurotoxin is an injection therapy that has been shown to be effective in treating a variety of painful musculoskeletal conditions, including osteoarthritis, plantar fasciopathy, and lateral elbow tendinopathy. [4]. We report the first published case of IAT successfully treated with botulinum toxin A (BTX-A).

Case presentation

A 57-year-old female presented with 12 months of progressively worsening right-sided heel pain. Pain onset was insidious, and she denied any previous mechanism of injury. The pain progressively worsened from a mild, dull ache to the point of debilitating pain with activities of daily living. She endorsed walking 150 minutes and two days of resistance training weekly, but her pain forced her to stop this exercise routine. She reported her pain as an eight out of 10 on the visual analog scale (VAS). A physical exam revealed marked tenderness to palpation over her right distal Achilles tendon insertion onto the calcaneus, exacerbated by resisted ankle plantar flexion. Thompson’s squeeze test and Achilles reflex were normal. Plain radiographs showed no bony abnormalities. Musculoskeletal ultrasound demonstrated a thickened distal Achilles tendon with multiple anechoic voids and calcifications consistent with calcific IAT (Figure 1).

Figure 1 Ultrasound image of Achilles tendon in long axis

Long axis ultrasound image of the Achilles tendon showing intratendinous calcifications (arrows) and alterations of echogenicity suggestive of chronic insertional tendinopathy.  

The patient received a home exercise prescription focusing on eccentric Achilles tendon loading consistent with the Alfredson protocol, with specific instructions to limit dorsiflexion past neutral to avoid compressive loading [3,5]. She had no improvement after 12 weeks and was unable to progress her rehabilitation due to pain. After a discussion of additional treatment options, a series of three intratendinous dextrose prolotherapy (DPT) injections were performed using 25% dextrose spaced six weeks apart, which was consistent with previous studies [6,7]. She reported an improvement of roughly 25%, but one week after each injection, she was back to her baseline pain without sustained improvement.

Subsequently, treatment options were re-addressed, with the patient deferring corticosteroid given the presence of significant tendinopathic changes. PRP injection was discussed but declined because of the patient's apprehension about the post-procedural pain. Given its successful use in the treatment of other chronic musculoskeletal conditions, the patient elected to pursue BTX-A injection [4]. After sterilizing the skin, a solution of 60 units of BTX-A mixed with normal saline for a total volume of 1 mL was injected into the right distal Achilles tendon at the calcaneal insertion under real-time ultrasound guidance (General Electric Venue Go, L4-12L-RS linear array transducer) with a 25-gauge 1.5-inch needle (Figure 2). This concentration of BTX-A was chosen based on a similar dosage used for lateral elbow tendinopathy [8]. The patient tolerated the procedure without complications and was instructed to limit activity for 48 hours and then resume activity as tolerated.

Figure 2 Ultrasound-guided injection of Achilles tendon

Image of an ultrasound-guided injection of BTX-A using a long-axis, in-plane approach directed at the area of the most notable tendinopathic changes (arrow).

BTX-A: botulinum toxin A

At her four-week follow-up, the patient reported the BTX-A injection provided a reduction in pain to a six on the VAS (25% improvement), and she reported that it was the first treatment that provided sustained relief. She denied paresthesia and showed no evidence of plantar flexion weakness. At eight weeks, the patient reported sustained 25% improvement and was able to ambulate and perform activities of daily living without significant discomfort. At 12 weeks, the patient was able to progress her eccentric load resistance and volume and reported continued improvement in her activity tolerance. At her six-month follow-up, she reported a reduction in pain to a four on the VAS (50% improvement), endorsed significant satisfaction with the procedure, and declined any additional injections.

Discussion

IAT is an injury caused by overuse and cumulative microtrauma, involving the tendon-bone interface from its insertion onto the calcaneus up to 2 cm proximally [9,10]. Patients with IAT present with heel pain at the distal tendon insertion at the calcaneus, and musculoskeletal ultrasound can demonstrate a disruption in the normal fibrillar architecture, tendon hypertrophy, neovascularization on color Doppler, and bursopathy [9]. Magnetic resonance imaging (MRI) is typically reserved for recalcitrant cases to rule out other soft tissue or bony pathology, further characterize tears seen on ultrasound, or to aid in interventional or surgical planning [9].

Non-operative care is the first line for treating IAT, though traditionally less successful compared to conservative mid-substance Achilles tendinopathy programs [11]. An exercise program specifically focusing on eccentric loading with reduced dorsiflexion has shown therapeutic benefits in IAT [5,11]. Extracorporeal shock wave therapy (ESWT) is another treatment option that has shown therapeutic benefit in IAT, with several clinical trials demonstrating similar results with a ≥2-point decrease in pain [10,11]. There is a consensus to avoid intratendinous corticosteroid injections due to concerns for exacerbating tendon degeneration and increasing the risk of rupture [9,10]. Hypertonic dextrose and PRP injections have shown therapeutic benefits, but the evidence is limited [6,7,11].

BTX-A is a potent neuromuscular blocking agent that has been shown to decrease pain in multiple musculoskeletal conditions [4]. Though the use of BTX-A for the treatment of chronic musculoskeletal conditions has been well-studied, its use for these conditions is considered off-label by the Food and Drug Administration (FDA). The use of BTX-A for painful musculoskeletal conditions is supported by two hypothesized mechanisms: a protective, paralyzing effect on muscles that reduces tendon tension and an analgesic effect due to inhibition of the neurotransmitters involved in pain transmission [12]. Adverse effects may include transient weakness of the injected muscle [4,8,12].

To the authors' knowledge, this is the first case to demonstrate the safe and successful use of ultrasound-guided BTX-A injection to treat recalcitrant IAT. In this case, the patient had confirmed IAT evidenced by exam and sonographic findings. The patient did not improve with an eccentric rehabilitation program and had a suboptimal response to DPT injections. As the patient declined other injection modalities and surgical referral, through shared decision-making, BTX-A injection was performed. The BTX-A injection was the only treatment that provided a sustained, significant improvement in her baseline pain. The BTX-A showed no adverse effects, and the patient was able to resume her daily activities without significant pain and advance her rehabilitation program. In IAT cases refractory to conservative management, BTX-A may be a safe and effective non-operative treatment option, though further studies are warranted.

Conclusions

IAT can be difficult to manage, as it is often refractory to various treatment modalities. This case demonstrates that BTX-A injection therapy may be a safe and effective treatment option for patients with recalcitrant IAT, though additional studies are needed to assess the optimal dosing and potential risks that may be associated with BTX-A injections performed within the Achilles tendon.

The views expressed in this material are those of the authors and do not reflect the official policy or position of the US government, the Department of Defense, or the Department of the Air Force.

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Alexander Kim, Alexander Knobloch, Carlton Covey

Acquisition, analysis, or interpretation of data:  Alexander Kim

Drafting of the manuscript:  Alexander Kim, Alexander Knobloch, Carlton Covey

Critical review of the manuscript for important intellectual content:  Alexander Kim, Alexander Knobloch, Carlton Covey

Supervision:  Alexander Kim
==== Refs
References

1 Achilles tendinopathy, a brief review and update of current literature Curr Sports Med Rep Vo TP Ho GW Andrea J 453 461 20 2021 34524189
2 Nonoperative treatment of insertional Achilles tendinopathy: a systematic review J Orthop Surg Res Zhi X Liu X Han J Xiang Y Wu H Wei S Xu F 233 16 2021 33785026
3 Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis Am J Sports Med Alfredson H Pietilä T Jonsson P Lorentzon R 360 366 26 1998 9617396
4 Utilization of botulinum toxin for musculoskeletal disorders Curr Sports Med Rep Moore C Hulsopple C Boyce B 217 222 19 2020 32516192
5 New regimen for eccentric calf-muscle training in patients with chronic insertional Achilles tendinopathy: results of a pilot study Br J Sports Med Jonsson P Alfredson H Sunding K Fahlström M Cook J 746 749 42 2008 18184750
6 Technical innovation case report: ultrasound-guided prolotherapy injection for insertional Achilles calcific tendinosis Case Rep Orthop Buchanan BK DeLuca JP Lammlein KP 1560161 2016 2016 27974984
7 Sonographically guided intratendinous injection of hyperosmolar dextrose to treat chronic tendinosis of the Achilles tendon: a pilot study Am J Roentgenol Maxwell NJ Ryan MB Taunton JE Gillies JH Wong AD 0 20 189 2007
8 The effect of botulinum toxin injection into the common extensor tendon in patients with chronic lateral epicondylitis: a randomized trial Pain Med Lee SH Choi HH Chang MC 1971 1976 21 2020 31804698
9 Achilles tendinopathy: evaluation, rehabilitation, and prevention Curr Sports Med Rep von Rickenbach KJ Borgstrom H Tenforde A Borg-Stein J McInnis KC 327 334 20 2021 34099611
10 Comparative short-term effectiveness of non-surgical treatments for insertional Achilles tendinopathy: a systematic review and network meta-analysis BMC Musculoskelet Disord Ko VM Cao M Qiu J Fong IC Fu SC Yung PS Ling SK 102 24 2023 36750789
11 Nonsurgical treatment options for insertional Achilles tendinopathy Foot Ankle Clin Dilger CP Chimenti RL 505 513 24 2019 31371000
12 Pain modulation in chronic musculoskeletal disorders: botulinum toxin, a descriptive analysis Biomedicines Poenaru D Sandulescu MI Cinteza D 1888 11 2023 37509527
